Suppr超能文献

移植前基于 FDG-PET 的复发/难治性霍奇金淋巴瘤生存模型:大剂量化疗和自体外周血造血干细胞移植后的结果。

Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.

机构信息

Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.

出版信息

Bone Marrow Transplant. 2013 Nov;48(12):1530-6. doi: 10.1038/bmt.2013.88. Epub 2013 Jun 10.

Abstract

Hodgkin's lymphoma (HL) patients with positive (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) post salvage chemotherapy or before high-dose chemotherapy and auto-SCT (HDC ASCT) have inferior outcomes. We reviewed 21 prognostic factors before salvage chemotherapy (at relapse/progression) and integrated post salvage FDG-PET results to develop a prognostic model for post HDC ASCT outcome. We used Fine and Gray method for competing risk analysis and regression model for risks assessment and outcome. One hundred and forty-one patients had post salvage FDG-PET before HDC ASCT (median age 25.5 years); male/female 55%:45%, relapsed/refractory 43%:57%, median follow-up 33 months. Multivariate analysis identified HL International Prognostic Score 3 (P=0.001; hazard ratio (HR): 3.7 (1.6-8.3)) and post salvage positive FDG-PET (P=0.011; HR: 3.4 (1.3-8.9)) with higher hazard of disease-specific death (model P=0.0001). Cumulative incidence of disease-specific death with 0, 1, 2 risk factors was 7%:29%:52%, respectively (P=0.00003). For disease-specific event (persistent, progressive or relapsed disease), mediastinal involvement (P=0.024; HR: 2.7 (1.14-6.5)), B symptoms (P=0.027; HR: 2.1 (1.09-4.2)) and positive post salvage FDG-PET (P=0.001; HR: 3.3 (1.7-6.7)) were significant (model P=<0.00001). Cumulative incidence of disease-specific event with 0, 1, 2, 3 risk factors was 8%:31%:50%:75%, respectively (P=0.0000006). Patients with higher scores have higher risk of treatment failure. They are potential candidates for newer therapies along with HDC ASCT.

摘要

霍奇金淋巴瘤(HL)患者在挽救化疗后(18)F-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)阳性或高剂量化疗和自体造血干细胞移植(HDC ASCT)前,预后较差。我们回顾了挽救化疗前(复发/进展时)的 21 个预后因素,并整合了挽救后 FDG-PET 结果,以建立 HDC ASCT 后预后模型。我们使用 Fine 和 Gray 方法进行竞争风险分析,使用回归模型进行风险评估和结局分析。141 例患者在 HDC ASCT 前进行了挽救后 FDG-PET(中位年龄 25.5 岁);男性/女性为 55%:45%,复发/难治性为 43%:57%,中位随访时间为 33 个月。多因素分析确定霍奇金淋巴瘤国际预后评分(HLIPS)≥3(P=0.001;危险比(HR):3.7(1.6-8.3))和挽救后 FDG-PET 阳性(P=0.011;HR:3.4(1.3-8.9))与疾病特异性死亡的风险更高(模型 P=0.0001)。无、1、2 个危险因素的疾病特异性死亡累积发生率分别为 7%:29%:52%(P=0.00003)。对于疾病特异性事件(持续存在、进展或复发疾病),纵隔受累(P=0.024;HR:2.7(1.14-6.5))、B 症状(P=0.027;HR:2.1(1.09-4.2))和挽救后 FDG-PET 阳性(P=0.001;HR:3.3(1.7-6.7))是显著的(模型 P<0.00001)。无、1、2、3 个危险因素的疾病特异性事件累积发生率分别为 8%:31%:50%:75%(P=0.0000006)。评分较高的患者有更高的治疗失败风险。他们是在 HDC ASCT 基础上应用新疗法的潜在候选者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验